drugset / Trial / NCT00725803
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to examine the safety, tolerability, pharmacokinetics (studies how the body processes a drug), and initial activity of GS-9450 in preventing liver damage due to scarring, or fibrosis, caused by Hepatitis C Virus (HCV) infection.
Timeline
- Start
- 2008-04
- Primary completion
- 2008-10
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NIVOCASAN | Small molecule | 5 mg | Oral |
| Subject | NIVOCASAN | Small molecule | 10 mg | Oral |
| Subject | NIVOCASAN | Small molecule | 40 mg | Oral |
| Subject | NIVOCASAN | Small molecule | 80 mg | Oral |